We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jacobs (JEC) Wins 1-Year ATOM Contract Extension from NASA
Read MoreHide Full Article
Jacobs Engineering Group Inc. has received a contract extension from NASA to provide aerospace testing, and facility operations and services at NASA’s Research Center in Mountain View, CA.
The Aerospace Testing and Facility Operation and Maintenance IV (“ATOM”) contract is now extended through February 2020. This brings the total contract value to $178 million.
Per the deal, Jacobs will continue supporting NASA Ames Research Center for operation, maintenance, repair and management of arc jets, wind tunnels, hypersonic facilities, and ballistics complexes. Further, these services will help the Aeronautics Research Mission directorate, Space Launch System and Orion Multi-Purpose Crew Vehicle, along with commercial and other government organizations.
Jacobs has been assisting NASA over the past 20 years. With this latest contract extension, it will continue to offer advanced R&D, scientific and technical solutions through Aerospace, Technology and Nuclear (ATN) line of business.
Recent ATN Contract Wins
On Mar 20, 2019, Jacobs clinched a deal from the U.S. Army Intelligence Center of Excellence (USAICoE) to train, develop and support the Army and other Department of Defense agencies at Fort Huachuca.
Per the contract, Jacobs will provide intelligence-related military occupational specialties and professional development educational services. The contract is valued at $785 million across seven and half years, if all options are exercised. It will provide the-above mentioned services at Davis Monthan AFB in Tucson, AZ; Corry Naval Station in Pensacola, FL; and Goodfellow AFB in San Angelo, TX.
Efficient project execution has been one of the main characteristics driving Jacobs’ performance over the last few quarters. This is evident from the company’s fiscal first-quarter 2019 backlog. Backlog (excluding discontinued business ECR) grew 8% year over year to $20.3 billion. Higher-margin ATN and Buildings, Infrastructure and Advanced Facilities (BIAF) line of businesses continue to see a robust pipeline of government and infrastructure-spending programs.
Notably, the ATN business (contributing 33.6% revenues in the fiscal first quarter) reported revenues of $1,035 million, increasing an impressive 45.6% year over year. Backlog in the segment also increased 7.8% from the prior-year quarter to $7.2 billion. The company projects three-year net organic revenues to witness a 3-5% CAGR, with a CAGR of 2-3% for ATN.
Share Price Performance
Jacobs’ shares have outperformed its industry over the past three months. The company’s shares have gained 33.7% compared with 32.2% growth of its industry in the said period. The price performance is backed by an impressive earnings surprise history, having surpassed the Zacks Consensus Estimates in six of the trailing seven quarters.
Quanta Services and Armstrong World’s earnings for the current year are expected to increase 4.3% and 12.6%, respectively.
Apergy has a solid three-five year expected EPS growth rate of 22.5%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Jacobs (JEC) Wins 1-Year ATOM Contract Extension from NASA
Jacobs Engineering Group Inc. has received a contract extension from NASA to provide aerospace testing, and facility operations and services at NASA’s Research Center in Mountain View, CA.
.jpg)
The Aerospace Testing and Facility Operation and Maintenance IV (“ATOM”) contract is now extended through February 2020. This brings the total contract value to $178 million.
Per the deal, Jacobs will continue supporting NASA Ames Research Center for operation, maintenance, repair and management of arc jets, wind tunnels, hypersonic facilities, and ballistics complexes. Further, these services will help the Aeronautics Research Mission directorate, Space Launch System and Orion Multi-Purpose Crew Vehicle, along with commercial and other government organizations.
Jacobs has been assisting NASA over the past 20 years. With this latest contract extension, it will continue to offer advanced R&D, scientific and technical solutions through Aerospace, Technology and Nuclear (ATN) line of business.
Recent ATN Contract Wins
On Mar 20, 2019, Jacobs clinched a deal from the U.S. Army Intelligence Center of Excellence (USAICoE) to train, develop and support the Army and other Department of Defense agencies at Fort Huachuca.
Per the contract, Jacobs will provide intelligence-related military occupational specialties and professional development educational services. The contract is valued at $785 million across seven and half years, if all options are exercised. It will provide the-above mentioned services at Davis Monthan AFB in Tucson, AZ; Corry Naval Station in Pensacola, FL; and Goodfellow AFB in San Angelo, TX.
Efficient project execution has been one of the main characteristics driving Jacobs’ performance over the last few quarters. This is evident from the company’s fiscal first-quarter 2019 backlog. Backlog (excluding discontinued business ECR) grew 8% year over year to $20.3 billion. Higher-margin ATN and Buildings, Infrastructure and Advanced Facilities (BIAF) line of businesses continue to see a robust pipeline of government and infrastructure-spending programs.
Notably, the ATN business (contributing 33.6% revenues in the fiscal first quarter) reported revenues of $1,035 million, increasing an impressive 45.6% year over year. Backlog in the segment also increased 7.8% from the prior-year quarter to $7.2 billion. The company projects three-year net organic revenues to witness a 3-5% CAGR, with a CAGR of 2-3% for ATN.
Share Price Performance
Jacobs’ shares have outperformed its industry over the past three months. The company’s shares have gained 33.7% compared with 32.2% growth of its industry in the said period. The price performance is backed by an impressive earnings surprise history, having surpassed the Zacks Consensus Estimates in six of the trailing seven quarters.
Zacks Rank & Stocks to Consider
Currently, Jacobs carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Zacks Construction sector include Quanta Services, Inc. (PWR - Free Report) , Apergy Corp. , and Armstrong World Industries, Inc. (AWI - Free Report) . While Quanta Services and Apergy sport a Zacks Rank #1 (Strong Buy), Armstrong World carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Quanta Services and Armstrong World’s earnings for the current year are expected to increase 4.3% and 12.6%, respectively.
Apergy has a solid three-five year expected EPS growth rate of 22.5%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>